First Atom Aims to Revolutionize Drug Design with 'Zero-Shot' AI

TAMPA, Fla. – March 30, 2026 – In a move signaling a profound shift in its strategy and ambition, biotechnology firm Asha Therapeutics today announced it has rebranded as First Atom Therapeutics. The new identity underscores the company's evolution into a "zero-shot de novo" drug design company, leveraging a powerful artificial intelligence platform to create entirely new medicines for some of the most challenging diseases known to medicine, including neurodegenerative, neuro-oncological, and rare diseases.

This rebranding is more than a name change; it represents a sharpened focus on a revolutionary approach that seeks to bypass the traditional, often inefficient, methods of drug discovery. By building new therapies atom by atom, First Atom is positioning itself at the vanguard of a new era in pharmaceutical development.

From Screening Billions to Designing One

For decades, the bedrock of drug discovery has been a numbers game: screening massive libraries of pre-made chemical compounds against a biological target, hoping for a hit. This process is time-consuming, expensive, and often fails to produce viable candidates. First Atom Therapeutics is built on a radically different philosophy.

The company’s core technology is a method called “zero-shot de novo drug design.” The “de novo” aspect means molecules are designed from scratch, not selected from a pre-existing library. This allows the exploration of a virtually infinite chemical space, creating the potential for entirely novel drugs. The “zero-shot” component is even more groundbreaking. It refers to the AI's ability to design a new molecule for a specific protein target without needing any prior examples of other molecules that successfully bind to it. Essentially, the AI can design a perfect key for a lock it has never seen before, based only on the intricate structure of the lock itself.

This is all powered by the company's proprietary PRISM Platform, an integrated system that combines artificial intelligence with physics-based simulations. Instead of random screening, PRISM designs bespoke chemical matter tailored to a specific binding site on a target protein. This precision engineering aims to not only accelerate the discovery process—potentially shrinking timelines from years to months—but also to create more effective and safer medicines by optimizing for multiple properties like potency, selectivity, and synthesizability from the very beginning.

A Strategic Rebrand Bolstered by Industry Titans

The company's new name, First Atom, was chosen to reflect this foundational approach to creating medicines. “The name First Atom incorporates our company’s approach to drug design from the outset - precise, foundational, and centered within the unlimited chemical space to create novel chemical entities with transformative potential,” commented Dr. Rainer Metcalf, the architect of the PRISM Platform who has been appointed as the company's Chief Technology Officer.

Dr. Metcalf's promotion underscores the centrality of the PRISM technology to the company's future. His vision is clear: “The origination of new drug concepts through rigorous design will define the next era of therapeutics.”

Adding significant weight and validation to this new chapter is the appointment of Dr. Wayne Guida as Senior Technology Advisor. Dr. Guida is a towering figure in the field of computational chemistry, having formerly served as President and CEO of Schrödinger, the industry leader in molecular modeling software. His pioneering work at CIBA-Geigy in the early days of structure-based drug design led to some of the first successful examples of the practice. His decision to join First Atom is a powerful endorsement of its technology and strategy, bringing decades of experience and a track record of commercial and scientific success to the team.

Targeting Medicine's Most Formidable Frontiers

First Atom is not shying away from difficulty; it is running toward it. The company has explicitly targeted therapeutic areas notorious for their complexity and high rates of clinical failure: neurodegenerative diseases, neuro-oncology, and rare diseases.

For conditions like Alzheimer's and Parkinson's disease, decades of research have yielded few treatments that can halt or reverse disease progression. The complexity of the brain and the subtle nature of these diseases make them incredibly difficult targets. First Atom's ability to design novel molecules may unlock new ways to modulate pathways that have so far been considered "undruggable."

In neuro-oncology, aggressive brain tumors like glioblastoma present a dual challenge: the tumor's own resilience and the formidable blood-brain barrier, which prevents most drugs from reaching their target. A platform that can design molecules specifically to be potent, target-specific, and capable of penetrating this barrier could represent a monumental leap forward for patients with grim prognoses.

Perhaps the greatest potential impact lies in the realm of rare diseases. An estimated 95% of the over 7,000 identified rare diseases have no approved treatment. The small patient populations often make traditional drug development economically unviable. AI-driven design, however, can create highly specific therapies for the unique genetic drivers of these conditions far more efficiently, offering hope to millions who have been left behind by modern medicine.

As the field of AI-driven drug discovery becomes increasingly competitive, First Atom is carving out its niche with a clear focus and a powerful technological premise. By combining a ground-up design philosophy with the expertise of seasoned industry leaders, the company aims to do more than just discover new drugs—it seeks to fundamentally redefine how they are created.

“First Atom is assembling a unique combination of scientific expertise, proven drug design capability, and strategic execution skill,” stated Dr. Guida. “I look forward to contributing to First Atom’s team and patient-centric culture as they continue to build out their drug design technology for the creation of critical new medicines.”